

**MEDICAL POLICY**

<b>POLICY TITLE</b>	<b>SENSORY INTEGRATION THERAPY AND AUDITORY INTEGRATION THERAPY</b>
<b>POLICY NUMBER</b>	<b>MP 8.011</b>

<b>Effective Date:</b>	<b>8/1/2023</b>
------------------------	-----------------

- |                                  |  |   |
|----------------------------------|--|---|
| <a href="#">POLICY RATIONALE</a> | <a href="#">PRODUCT VARIATIONS DEFINITIONS</a> | <a href="#">DESCRIPTION/BACKGROUND BENEFIT VARIATIONS</a> |
| <a href="#">DISCLAIMER</a>       | <a href="#">CODING INFORMATION</a>             | <a href="#">REFERENCES</a>                                |
| <a href="#">POLICY HISTORY</a>   |  |   |

**I. POLICY**

Sensory integration therapy and auditory integration therapy are considered **investigational**. There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure.

**Note:** Investigational status does not apply to members/groups whose benefits are subject to the terms mandated in Pennsylvania Act 62 of 2008.

***Cross-references:***

- MP 8.007** Cognitive Rehabilitation
- MP 8.004** Occupational Therapy (Outpatient)
- MP 2.304** Autism Spectrum Disorders
- MP 8.001** Physical Medicine and Specialized Physical Medicine Treatments (Outpatient)

**II. PRODUCT VARIATIONS**

[TOP](#)

This policy is only applicable to certain programs and products administered by Capital Blue Cross and subject to benefit variations as discussed in Section VI. Please see additional information below.

FEP PPO - Refer to FEP Medical Policy Manual. The FEP Medical Policy manual can be found at: <https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>

**III. DESCRIPTION/BACKGROUND**

[TOP](#)

The goal of sensory integration therapy (SIT) is to improve how the brain processes and adapts to sensory information, as opposed to teaching specific skills. Therapy usually involves activities that provide vestibular, proprioceptive, and tactile stimuli, which are selected to match specific sensory processing deficits of the child. For example, swings are commonly used to incorporate vestibular input, while trapeze bars and large foam pillows or mats may be used to stimulate somatosensory pathways of proprioception and deep touch. Tactile reception may be addressed through a variety of activities and surface textures involving light touch.

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>SENSORY INTEGRATION THERAPY AND AUDITORY INTEGRATION THERAPY</b>
<b>POLICY NUMBER</b>	<b>MP 8.011</b>

Auditory integration therapy (AIT; also known as auditory integration training, auditory enhancement training, audio-psycho-phonology) involves having individuals listen to music modified to remove frequencies to which they are hypersensitive, with the goal of gradually increasing exposure to sensitive frequencies. Although several methods of AIT have been developed, the most widely described is the Berard method, which involves two half-hour sessions per day separated by at least three hours, over 10 consecutive days, during which patients listen to recordings. AIT has been proposed for individuals with a range of developmental and behavioral disorders, including learning disabilities, autism spectrum disorder, pervasive developmental disorder, and attention-deficit/hyperactivity disorder. Other methods include the Tomatis method, which involves listening to electronically modified music and speech, and Samonas Sound Therapy, which involves listening to filtered music, voices, and nature sounds.

### Regulatory Status

SIT is a procedure and, as such, is not subject to regulation by the U.S. Food and Drug Administration. No devices designed to provide AIT have been cleared for marketing by the Food and Drug Administration.

## IV. RATIONALE

[TOP](#)

### SUMMARY OF EVIDENCE

For individuals who have developmental disorders who receive SIT, the evidence includes systematic reviews of randomized controlled trials and case series. Relevant outcomes are functional outcomes and quality of life. Due to the individualized approach to SIT and the large variations in patients' disorders, large multicenter RCTs are needed to evaluate the efficacy of this intervention. The most direct evidence on SIT outcomes derives from several small randomized trials. Although some of these trials demonstrated improvements for subsets of outcomes measured, they had small sample sizes, heterogeneous patient populations, and variable outcome measures. A randomized controlled trial of 138 children ages 4 to 11 years published in 2022 found that sensory integration therapy for children with autism and sensory processing difficulties did not demonstrate clinical benefit above standard care. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have developmental disorders who receive AIT, the evidence includes systematic reviews of randomized controlled trials. Relevant outcomes are functional outcomes and quality of life. For AIT, the largest body of literature relates to its use in autism spectrum disorder. Several systematic reviews of AIT in the treatment of autism have found limited evidence to support its use. No comparative studies identified evaluated use of AIT for other conditions. The evidence is insufficient to determine the effects of the technology on health outcomes.

**MEDICAL POLICY**

<b>POLICY TITLE</b>	<b>SENSORY INTEGRATION THERAPY AND AUDITORY INTEGRATION THERAPY</b>
<b>POLICY NUMBER</b>	<b>MP 8.011</b>

**V. DEFINITIONS**

[TOP](#)

**PROPRIOCEPTION** is the mechanism involved in the self-regulation of posture and movement through stimuli originating in the receptors imbedded in the joints, tendons, muscles, and labyrinth.

**SOMATOSENSORY** is considered one of the five traditional senses also known as touch. The impression of touch is formed from several modalities. In medicine, the colloquial term touch is usually replaced with somatic senses to better reflect the variety of mechanisms involved.

**VI. BENEFIT VARIATIONS**

[TOP](#)

The existence of this medical policy does not mean that this service is a covered benefit under the member's health benefit plan. Benefit determinations should be based in all cases on the applicable health benefit plan language. Medical policies do not constitute a description of benefits. A member's health benefit plan governs which services are covered, which are excluded, which are subject to benefit limits and which require preauthorization. There are different benefit plan designs in each product administered by Capital Blue Cross. Members and providers should consult the member's health benefit plan for information or contact Capital Blue Cross for benefit information.

**VII. DISCLAIMER**

[TOP](#)

*Capital Blue Cross's medical policies are developed to assist in administering a member's benefits, do not constitute medical advice, and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical policy and a member's benefit information, the benefit information will govern. If a provider or a member has a question concerning the application of this medical policy to a specific member's plan of benefits, please contact Capital Blue Cross' Provider Services or Member Services. Capital Blue Cross considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.*

**VIII. CODING INFORMATION**

[TOP](#)

**Note:** This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

**Investigational; therefore not covered:**

Procedure Codes							
97533							

**MEDICAL POLICY**

<b>POLICY TITLE</b>	<b>SENSORY INTEGRATION THERAPY AND AUDITORY INTEGRATION THERAPY</b>
<b>POLICY NUMBER</b>	<b>MP 8.011</b>

**IX. REFERENCES**

[TOP](#)

1. Sinha Y, Silove N, Hayen A, et al. Auditory integration training and other sound therapies for autism spectrum disorders (ASD). *Cochrane Database Syst Rev*. Dec 07 2011; 2011(12): CD003681. PMID 22161380
2. Schaaf RC, Burke JP, Cohn E, et al. State of measurement in occupational therapy using sensory integration. *Am J Occup Ther*. 2014; 68(5): e149-53. PMID 25184475
3. Mailloux Z, May-Benson TA, Summers CA, et al. Goal attainment scaling as a measure of meaningful outcomes for children with sensory integration disorders. *Am J Occup Ther*. 2007; 61(2): 254-9. PMID 17436848
4. Parham LD, Cohn ES, Spitzer S, et al. Fidelity in sensory integration intervention research. *Am J Occup Ther*. 2007; 61(2): 216-27. PMID 17436844
5. Weitlauf AS, Sathe N, McPheeters ML, et al. Interventions Targeting Sensory Challenges in Autism Spectrum Disorder: A Systematic Review. *Pediatrics*. Jun 2017; 139(6). PMID 28562287
6. Case-Smith J, Weaver LL, Fristad MA. A systematic review of sensory processing interventions for children with autism spectrum disorders. *Autism*. Feb 2015; 19(2): 133-48. PMID 24477447
7. May-Benson TA, Koomar JA. Systematic review of the research evidence examining the effectiveness of interventions using a sensory integrative approach for children. *Am J Occup Ther*. 2010; 64(3): 403-14. PMID 20608272
8. Randell E, Wright M, Milosevic S, et al. Sensory integration therapy for children with autism and sensory processing difficulties: the SenITA RCT. *Health Technol Assess*. Jun 2022; 26(29): 1-140. PMID 35766242
9. Corbett BA, Shickman K, Ferrer E. Brief report: the effects of Tomatis sound therapy on language in children with autism. *J Autism Dev Disord*. Mar 2008; 38(3): 562-6. PMID 17610057
10. Mudford OC, Cross BA, Breen S, et al. Auditory integration training for children with autism: no behavioral benefits detected. *Am J Ment Retard*. Mar 2000; 105(2): 118-29. PMID 10755175
11. Porges SW, Bazhenova OV, Bal E, et al. Reducing auditory hypersensitivities in autistic spectrum disorder: preliminary findings evaluating the listening project protocol. *Front Pediatr*. 2014; 2: 80. PMID 25136545
12. Brondino N, Fusar-Poli L, Rocchetti M, et al. Complementary and Alternative Therapies for Autism Spectrum Disorder. *Evid Based Complement Alternat Med*. 2015; 2015: 258589. PMID 26064157
13. Zimmer M, Desch L, Rosen LD, et al. Sensory integration therapies for children with developmental and behavioral disorders. *Pediatrics*. Jun 2012; 129(6): 1186-9. PMID 22641765
14. Occupational Therapy for Children and Youth Using Sensory Integration Theory and Methods in School-Based Practice. *Am J Occup Ther*. 2015; 69 Suppl 3: 6913410040p1-6913410040p20. PMID 26713950

**MEDICAL POLICY**

<b>POLICY TITLE</b>	<b>SENSORY INTEGRATION THERAPY AND AUDITORY INTEGRATION THERAPY</b>
<b>POLICY NUMBER</b>	<b>MP 8.011</b>

15. *Watling R, Koenig KP, Davies PL, et al. Occupational therapy practice guidelines for children and adolescents with challenges in sensory processing and sensory integration. Bethesda, MD: American Occupational Therapy Association Press; 2011*
16. *American Speech-Language-Hearing Association, Working Group in AIT. Auditory Integration Training [Technical Report:]. 2004*
17. *Blue Cross Blue Shield Association Medical Policy Reference Manual. 8.03.13, Sensory Integration and Auditory Integration Therapy. April 2023*

**X. POLICY HISTORY**

[TOP](#)

<b>MP-8.011</b>	<b>CAC 04/26/2011</b> New policy. Sensory integration therapy statement was changed from not medically necessary to investigational. Adopt BCBSA. Added note indicating investigational status does not apply to members/groups whose benefits are subject to the terms mandated in Pennsylvania Act 62 of 2008.
	<b>CAC 06/26/2012 Consensus</b> , no change to policy statement, references updated. Added FEP variation to reference FEP Medical Policy Manual MP-8.03.13 Sensory Integration Therapy.
	<b>07/25/2013</b> Admin coding review complete
	<b>CAC 09/24/2013 Consensus</b> . No change to policy statement. References updated. Rationale section added.
	<b>CAC 09/30/2014 Consensus</b> . No change to policy statements. References updated. Coding reviewed.
	<b>11/02/2015</b> Administrative change. LCD number changed from L27513 and L27531 to L35044 and L35070 due to Novitas update to ICD-10.
	<b>CAC 06/02/2015 Minor policy review</b> . Statement expanded to include investigational statement for auditory integration therapy. Title changed to reflect inclusion of auditory integration therapy. Rationale and references updated.
	<b>Medicare change 05/12/2016</b> Changed LCD variation to reference L35036 Therapy and Rehabilitation Services (PT, OT). L35044 Physical Medicine & Rehabilitation Services, Physical Therapy, and Occupational Therapy retired by Novitas effective 4/7/16
	<b>CAC 05/31/2016 Consensus review</b> . No changes to the policy statements. References and rationale updated. Coding reviewed.
	<b>Admin update 01/01/2017</b> : Product variation section reformatted.
	<b>CAC 05/23/2017 Consensus review</b> . No changes to the policy statements. References reviewed. Rationale updated. Coding reviewed.
	<b>01/01/2018 Admin Update</b> : Medicare variations removed from Commercial Policies.
<b>03/19/2018 Consensus review</b> . Policy statement unchanged. Description/Background, Rationale, and Reference sections updated.	

**MEDICAL POLICY**

<b>POLICY TITLE</b>	<b>SENSORY INTEGRATION THERAPY AND AUDITORY INTEGRATION THERAPY</b>
<b>POLICY NUMBER</b>	<b>MP 8.011</b>

<b>02/21/2019 Consensus review.</b> No changes to the policy statement. Background updated. References reviewed. Rationale revised.
<b>02/26/2020 Consensus review,</b> no changes to coding or policy statement.
<b>05/19/2021 Consensus review.</b> No change to policy statement. References updated.
<b>04/05/2022 Consensus review.</b> No change to policy statement. Coding table format updated. FEP language updated.
<b>4/27/2023 Consensus review.</b> No change to policy statement. Rationale updated. References reviewed and updated. No coding change.

[Top](#)

*Health care benefit programs issued or administered by Capital Blue Cross and/or its subsidiaries, Capital Advantage Insurance Company® and Keystone Health Plan® Central. Independent licensees of the Blue Cross and Blue Shield Association. Communications issued by Capital Blue Cross in its capacity as administrator of programs and provider relations for all companies.*